Scientific Sessions 2025  /  Groundbreaking Trials in Cardiometabolic Therapeutics  /  Discussant
Logo

American Heart Association

  31
  0

Final ID:

Discussant

  • Lingvay, Ildiko  ( UT Southwestern Medical Center , Dallas , Texas , United States )
  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
    • Author Disclosures:
    Ildiko Lingvay: DO have relevant financial relationships ; Research Funding (PI or named investigator):Boehringer Ingelheim:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Janssen:Active (exists now) ; Consultant:Betagenon:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Consultant:Alveus Therapeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:AbbVie:Active (exists now) ; Research Funding (PI or named investigator):Roche:Active (exists now) ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Lilly:Active (exists now) ; Research Funding (PI or named investigator):Dexcom:Active (exists now) | Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Groundbreaking Trials in Cardiometabolic Therapeutics

Saturday, 11/08/2025 , 08:30AM - 09:45AM

Late-Breaking Science

More abstracts on this topic:
Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke: Primary Results of the VESALIUS-CV trial

Bohula Erin, Wang Huei, Cyrille Marcoli, Paiva Da Silva Lima Gabriel, Giugliano Robert, Sabatine Marc, Marston Nicholas, Bhatia Ajay, De Ferrari Gaetano Maria, Leiter Lawrence, Nicolau Jose, Park Jeong-gun, Murphy Sabina, Walsh Emileigh

First-in-Human Phase 1 Clinical Trial of a CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Nicholls Stephen, Patel Naimish, Duran Jason, Nissen Steven, Laffin Luke, Scott Russell, Clifton Peter, Baker John, Sarraju Ashish, Singh Shweta, Xu Huansheng, Nielsen Jennifer

More abstracts from these authors:
ANGPTL3 inhibitors for reduction of cardiovascular disease risk

Rosenson Robert

How do we SELECT incretin analogues and SUSTAIN their impact? Clinical approaches for short and long-term obesity care

Jastreboff Ania, Lingvay Ildiko

You have to be authorized to contact abstract author. Please, Login
Not Available